#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Obesity and related disorders are widely perceived by both the public and the scientific community as a major and growing threat to global human health ; more than 2 billion people worldwide are currently overweight or obese , and obesity is associated with an increased hazard for a range of ailments , including type-2 diabetes , cardiovascular diseases and hypertension , multiple cancer types , chronic inflammatory diseases , dementia , and neurodegenerative diseases .
2-1	16-23	Obesity	abstract|abstract[3]	new|new[3]	coref|coref	2-40|13-12[104_3]
2-2	24-27	and	abstract[3]	new[3]	_	_
2-3	28-35	related	abstract[3]|abstract[4]	new[3]|new[4]	coref	13-14[105_4]
2-4	36-45	disorders	abstract[3]|abstract[4]	new[3]|new[4]	_	_
2-5	46-49	are	_	_	_	_
2-6	50-56	widely	_	_	_	_
2-7	57-66	perceived	_	_	_	_
2-8	67-69	by	_	_	_	_
2-9	70-74	both	person[5]	new[5]	_	_
2-10	75-78	the	person[5]	new[5]	_	_
2-11	79-85	public	person[5]	new[5]	_	_
2-12	86-89	and	_	_	_	_
2-13	90-93	the	organization[6]	new[6]	_	_
2-14	94-104	scientific	organization[6]	new[6]	_	_
2-15	105-114	community	organization[6]	new[6]	_	_
2-16	115-117	as	organization[6]	new[6]	_	_
2-17	118-119	a	organization[6]	new[6]	_	_
2-18	120-125	major	organization[6]	new[6]	_	_
2-19	126-129	and	organization[6]	new[6]	_	_
2-20	130-137	growing	organization[6]	new[6]	_	_
2-21	138-144	threat	organization[6]	new[6]	_	_
2-22	145-147	to	organization[6]	new[6]	_	_
2-23	148-154	global	organization[6]|abstract[7]	new[6]|new[7]	_	_
2-24	155-160	human	organization[6]|abstract[7]	new[6]|new[7]	_	_
2-25	161-167	health	organization[6]|abstract[7]	new[6]|new[7]	_	_
2-26	168-169	;	_	_	_	_
2-27	170-174	more	person[10]	new[10]	_	_
2-28	175-179	than	person[10]	new[10]	_	_
2-29	180-181	2	quantity|person[10]	new|new[10]	_	_
2-30	182-189	billion	abstract|person[10]	new|new[10]	_	_
2-31	190-196	people	person[10]	new[10]	_	_
2-32	197-206	worldwide	person[10]	new[10]	_	_
2-33	207-210	are	_	_	_	_
2-34	211-220	currently	_	_	_	_
2-35	221-231	overweight	_	_	_	_
2-36	232-234	or	_	_	_	_
2-37	235-240	obese	_	_	_	_
2-38	241-242	,	_	_	_	_
2-39	243-246	and	_	_	_	_
2-40	247-254	obesity	abstract	giv	coref	4-20
2-41	255-257	is	_	_	_	_
2-42	258-268	associated	_	_	_	_
2-43	269-273	with	_	_	_	_
2-44	274-276	an	abstract[12]	new[12]	_	_
2-45	277-286	increased	abstract[12]	new[12]	_	_
2-46	287-293	hazard	abstract[12]	new[12]	_	_
2-47	294-297	for	abstract[12]	new[12]	_	_
2-48	298-299	a	abstract[12]	new[12]	_	_
2-49	300-305	range	abstract[12]	new[12]	_	_
2-50	306-308	of	abstract[12]	new[12]	_	_
2-51	309-317	ailments	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-52	318-319	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-53	320-329	including	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-54	330-336	type-2	abstract[12]|abstract[13]|abstract[14]	new[12]|new[13]|new[14]	_	_
2-55	337-345	diabetes	abstract[12]|abstract[13]|abstract[14]	new[12]|new[13]|new[14]	_	_
2-56	346-347	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-57	348-362	cardiovascular	abstract[12]|abstract[13]|abstract[15]	new[12]|new[13]|new[15]	_	_
2-58	363-371	diseases	abstract[12]|abstract[13]|abstract[15]	new[12]|new[13]|new[15]	_	_
2-59	372-375	and	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-60	376-388	hypertension	abstract[12]|abstract[13]|abstract	new[12]|new[13]|new	_	_
2-61	389-390	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-62	391-399	multiple	abstract[12]|abstract[13]|abstract[18]	new[12]|new[13]|new[18]	_	_
2-63	400-406	cancer	abstract[12]|abstract[13]|abstract|abstract[18]	new[12]|new[13]|new|new[18]	_	_
2-64	407-412	types	abstract[12]|abstract[13]|abstract[18]	new[12]|new[13]|new[18]	_	_
2-65	413-414	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-66	415-422	chronic	abstract[12]|abstract[13]|abstract[19]	new[12]|new[13]|new[19]	_	_
2-67	423-435	inflammatory	abstract[12]|abstract[13]|abstract[19]	new[12]|new[13]|new[19]	_	_
2-68	436-444	diseases	abstract[12]|abstract[13]|abstract[19]	new[12]|new[13]|new[19]	_	_
2-69	445-446	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-70	447-455	dementia	abstract[12]|abstract[13]|abstract	new[12]|new[13]|new	_	_
2-71	456-457	,	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-72	458-461	and	abstract[12]|abstract[13]	new[12]|new[13]	_	_
2-73	462-479	neurodegenerative	abstract[12]|abstract[13]|abstract[21]	new[12]|new[13]|new[21]	_	_
2-74	480-488	diseases	abstract[12]|abstract[13]|abstract[21]	new[12]|new[13]|new[21]	_	_
2-75	489-490	.	_	_	_	_

#Text=All these complications lead to a shortened life expectancy and have a high economic impact on healthcare systems .
3-1	491-494	All	abstract[22]	new[22]	_	_
3-2	495-500	these	abstract[22]	new[22]	_	_
3-3	501-514	complications	abstract[22]	new[22]	_	_
3-4	515-519	lead	_	_	_	_
3-5	520-522	to	_	_	_	_
3-6	523-524	a	abstract[24]	new[24]	_	_
3-7	525-534	shortened	abstract[24]	new[24]	_	_
3-8	535-539	life	abstract|abstract[24]	new|new[24]	_	_
3-9	540-550	expectancy	abstract[24]	new[24]	_	_
3-10	551-554	and	_	_	_	_
3-11	555-559	have	_	_	_	_
3-12	560-561	a	abstract[25]	new[25]	_	_
3-13	562-566	high	abstract[25]	new[25]	_	_
3-14	567-575	economic	abstract[25]	new[25]	_	_
3-15	576-582	impact	abstract[25]	new[25]	_	_
3-16	583-585	on	abstract[25]	new[25]	_	_
3-17	586-596	healthcare	abstract[25]|organization|abstract[27]	new[25]|new|new[27]	_	_
3-18	597-604	systems	abstract[25]|abstract[27]	new[25]|new[27]	_	_
3-19	605-606	.	_	_	_	_

#Text=Lifestyle changes ( such as diet modification , physical activity , and behavioral interventions ) are the cornerstones of obesity treatment but maintaining a healthy lifestyle is often perceived as challenging .
4-1	607-616	Lifestyle	abstract|abstract[29]	new|new[29]	coref|coref	4-17[34_29]|4-24[37_0]
4-2	617-624	changes	abstract[29]	new[29]	_	_
4-3	625-626	(	abstract[29]	new[29]	_	_
4-4	627-631	such	abstract[29]	new[29]	_	_
4-5	632-634	as	abstract[29]	new[29]	_	_
4-6	635-639	diet	abstract[29]|event|abstract[31]	new[29]|new|new[31]	_	_
4-7	640-652	modification	abstract[29]|abstract[31]	new[29]|new[31]	_	_
4-8	653-654	,	abstract[29]	new[29]	_	_
4-9	655-663	physical	abstract[29]|abstract[32]	new[29]|new[32]	coref	20-26[182_32]
4-10	664-672	activity	abstract[29]|abstract[32]	new[29]|new[32]	_	_
4-11	673-674	,	abstract[29]	new[29]	_	_
4-12	675-678	and	abstract[29]	new[29]	_	_
4-13	679-689	behavioral	abstract[29]|event[33]	new[29]|new[33]	coref	5-8[41_33]
4-14	690-703	interventions	abstract[29]|event[33]	new[29]|new[33]	_	_
4-15	704-705	)	abstract[29]	new[29]	_	_
4-16	706-709	are	_	_	_	_
4-17	710-713	the	abstract[34]	giv[34]	coref	14-47[0_34]
4-18	714-726	cornerstones	abstract[34]	giv[34]	_	_
4-19	727-729	of	abstract[34]	giv[34]	_	_
4-20	730-737	obesity	abstract[34]|abstract|event[36]	giv[34]|giv|new[36]	coref|coref	6-4|24-20[211_36]
4-21	738-747	treatment	abstract[34]|event[36]	giv[34]|new[36]	_	_
4-22	748-751	but	_	_	_	_
4-23	752-763	maintaining	_	_	_	_
4-24	764-765	a	abstract[37]	giv[37]	_	_
4-25	766-773	healthy	abstract[37]	giv[37]	_	_
4-26	774-783	lifestyle	abstract[37]	giv[37]	_	_
4-27	784-786	is	_	_	_	_
4-28	787-792	often	_	_	_	_
4-29	793-802	perceived	_	_	_	_
4-30	803-805	as	_	_	_	_
4-31	806-817	challenging	_	_	_	_
4-32	818-819	.	_	_	_	_

#Text=Alternatively , pharmacotherapy and bariatric surgery represent more “ aggressive ” interventions , and are applicable only if the problem is severe .
5-1	820-833	Alternatively	_	_	_	_
5-2	834-835	,	_	_	_	_
5-3	836-851	pharmacotherapy	abstract	new	coref	6-1[43_0]
5-4	852-855	and	_	_	_	_
5-5	856-865	bariatric	abstract|event[40]	new|new[40]	_	_
5-6	866-873	surgery	event[40]	new[40]	_	_
5-7	874-883	represent	_	_	_	_
5-8	884-888	more	event[41]	giv[41]	_	_
5-9	889-890	“	event[41]	giv[41]	_	_
5-10	891-901	aggressive	event[41]	giv[41]	_	_
5-11	902-903	”	event[41]	giv[41]	_	_
5-12	904-917	interventions	event[41]	giv[41]	_	_
5-13	918-919	,	_	_	_	_
5-14	920-923	and	_	_	_	_
5-15	924-927	are	_	_	_	_
5-16	928-938	applicable	_	_	_	_
5-17	939-943	only	_	_	_	_
5-18	944-946	if	_	_	_	_
5-19	947-950	the	abstract[42]	new[42]	_	_
5-20	951-958	problem	abstract[42]	new[42]	_	_
5-21	959-961	is	_	_	_	_
5-22	962-968	severe	_	_	_	_
5-23	969-970	.	_	_	_	_

#Text=Current pharmacotherapy for obesity relies on a few drugs that are approved only for patients with BMI > 30 .
6-1	971-978	Current	abstract[43]	giv[43]	_	_
6-2	979-994	pharmacotherapy	abstract[43]	giv[43]	_	_
6-3	995-998	for	abstract[43]	giv[43]	_	_
6-4	999-1006	obesity	abstract[43]|abstract	giv[43]|giv	coref	13-12
6-5	1007-1013	relies	_	_	_	_
6-6	1014-1016	on	_	_	_	_
6-7	1017-1018	a	substance[45]	new[45]	coref	7-17[54_45]
6-8	1019-1022	few	substance[45]	new[45]	_	_
6-9	1023-1028	drugs	substance[45]	new[45]	_	_
6-10	1029-1033	that	_	_	_	_
6-11	1034-1037	are	_	_	_	_
6-12	1038-1046	approved	_	_	_	_
6-13	1047-1051	only	_	_	_	_
6-14	1052-1055	for	_	_	_	_
6-15	1056-1064	patients	person[46]	new[46]	_	_
6-16	1065-1069	with	person[46]	new[46]	_	_
6-17	1070-1073	BMI	person[46]|organization[47]	new[46]|new[47]	_	_
6-18	1074-1075	>	person[46]|organization[47]	new[46]|new[47]	_	_
6-19	1076-1078	30	person[46]|organization[47]|quantity	new[46]|new[47]|new	_	_
6-20	1079-1080	.	_	_	_	_

#Text=With the only exception of orlistat ( which decreases fat absorption by inhibiting lipases ) , most of these drugs act through the central nervous system to reduce food intake ( via reduction of appetite or enhancement of satiety ) .
7-1	1081-1085	With	_	_	_	_
7-2	1086-1089	the	abstract[49]	new[49]	_	_
7-3	1090-1094	only	abstract[49]	new[49]	_	_
7-4	1095-1104	exception	abstract[49]	new[49]	_	_
7-5	1105-1107	of	abstract[49]	new[49]	_	_
7-6	1108-1116	orlistat	abstract[49]|substance	new[49]|new	_	_
7-7	1117-1118	(	_	_	_	_
7-8	1119-1124	which	_	_	_	_
7-9	1125-1134	decreases	_	_	_	_
7-10	1135-1138	fat	substance|abstract[52]	new|new[52]	coref	14-9
7-11	1139-1149	absorption	abstract[52]	new[52]	_	_
7-12	1150-1152	by	_	_	_	_
7-13	1153-1163	inhibiting	_	_	_	_
7-14	1164-1171	lipases	substance	new	_	_
7-15	1172-1173	)	_	_	_	_
7-16	1174-1175	,	_	_	_	_
7-17	1176-1180	most	substance[54]	giv[54]	_	_
7-18	1181-1183	of	substance[54]	giv[54]	_	_
7-19	1184-1189	these	substance[54]	giv[54]	_	_
7-20	1190-1195	drugs	substance[54]	giv[54]	_	_
7-21	1196-1199	act	_	_	_	_
7-22	1200-1207	through	_	_	_	_
7-23	1208-1211	the	object[55]	new[55]	_	_
7-24	1212-1219	central	object[55]	new[55]	_	_
7-25	1220-1227	nervous	object[55]	new[55]	_	_
7-26	1228-1234	system	object[55]	new[55]	_	_
7-27	1235-1237	to	_	_	_	_
7-28	1238-1244	reduce	_	_	_	_
7-29	1245-1249	food	substance|event[57]	new|new[57]	_	_
7-30	1250-1256	intake	event[57]	new[57]	_	_
7-31	1257-1258	(	event[57]	new[57]	_	_
7-32	1259-1262	via	event[57]	new[57]	_	_
7-33	1263-1272	reduction	event[57]|abstract[58]	new[57]|new[58]	_	_
7-34	1273-1275	of	event[57]|abstract[58]	new[57]|new[58]	_	_
7-35	1276-1284	appetite	event[57]|abstract[58]|abstract	new[57]|new[58]|new	_	_
7-36	1285-1287	or	event[57]|abstract[58]	new[57]|new[58]	_	_
7-37	1288-1299	enhancement	event[57]|abstract[58]|abstract[60]	new[57]|new[58]|new[60]	_	_
7-38	1300-1302	of	event[57]|abstract[58]|abstract[60]	new[57]|new[58]|new[60]	_	_
7-39	1303-1310	satiety	event[57]|abstract[58]|abstract[60]|abstract	new[57]|new[58]|new[60]|new	_	_
7-40	1311-1312	)	event[57]	new[57]	_	_
7-41	1313-1314	.	_	_	_	_

#Text=However , the use of these treatments may lead to severe adverse effects and a long-term prescription is usually not recommended .
8-1	1315-1322	However	_	_	_	_
8-2	1323-1324	,	_	_	_	_
8-3	1325-1328	the	event[62]	new[62]	_	_
8-4	1329-1332	use	event[62]	new[62]	_	_
8-5	1333-1335	of	event[62]	new[62]	_	_
8-6	1336-1341	these	event[62]|abstract[63]	new[62]|new[63]	coref	9-25[73_63]
8-7	1342-1352	treatments	event[62]|abstract[63]	new[62]|new[63]	_	_
8-8	1353-1356	may	_	_	_	_
8-9	1357-1361	lead	_	_	_	_
8-10	1362-1364	to	_	_	_	_
8-11	1365-1371	severe	abstract[64]	new[64]	coref	9-30[75_64]
8-12	1372-1379	adverse	abstract[64]	new[64]	_	_
8-13	1380-1387	effects	abstract[64]	new[64]	_	_
8-14	1388-1391	and	_	_	_	_
8-15	1392-1393	a	event[65]	new[65]	_	_
8-16	1394-1403	long-term	event[65]	new[65]	_	_
8-17	1404-1416	prescription	event[65]	new[65]	_	_
8-18	1417-1419	is	_	_	_	_
8-19	1420-1427	usually	_	_	_	_
8-20	1428-1431	not	_	_	_	_
8-21	1432-1443	recommended	_	_	_	_
8-22	1444-1445	.	_	_	_	_

#Text=A nutraceutical approach could be a useful supporting tool to treat overweight people , since the use of natural compounds offers clear advantages over drug treatments in terms of adverse side effects , suitability for chronic treatments , marketability , and safety .
9-1	1446-1447	A	abstract[66]	new[66]	coref	9-6[67_66]
9-2	1448-1461	nutraceutical	abstract[66]	new[66]	_	_
9-3	1462-1470	approach	abstract[66]	new[66]	_	_
9-4	1471-1476	could	_	_	_	_
9-5	1477-1479	be	_	_	_	_
9-6	1480-1481	a	abstract[67]	giv[67]	_	_
9-7	1482-1488	useful	abstract[67]	giv[67]	_	_
9-8	1489-1499	supporting	abstract[67]	giv[67]	_	_
9-9	1500-1504	tool	abstract[67]	giv[67]	_	_
9-10	1505-1507	to	_	_	_	_
9-11	1508-1513	treat	_	_	_	_
9-12	1514-1524	overweight	person[68]	giv[68]	_	_
9-13	1525-1531	people	person[68]	giv[68]	_	_
9-14	1532-1533	,	_	_	_	_
9-15	1534-1539	since	_	_	_	_
9-16	1540-1543	the	event[69]	new[69]	_	_
9-17	1544-1547	use	event[69]	new[69]	_	_
9-18	1548-1550	of	event[69]	new[69]	_	_
9-19	1551-1558	natural	event[69]|substance[70]	new[69]|new[70]	_	_
9-20	1559-1568	compounds	event[69]|substance[70]	new[69]|new[70]	_	_
9-21	1569-1575	offers	_	_	_	_
9-22	1576-1581	clear	abstract[71]	new[71]	_	_
9-23	1582-1592	advantages	abstract[71]	new[71]	_	_
9-24	1593-1597	over	abstract[71]	new[71]	_	_
9-25	1598-1602	drug	abstract[71]|substance|abstract[73]	new[71]|new|giv[73]	_	_
9-26	1603-1613	treatments	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-27	1614-1616	in	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-28	1617-1622	terms	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-29	1623-1625	of	abstract[71]|abstract[73]	new[71]|giv[73]	_	_
9-30	1626-1633	adverse	abstract[71]|abstract[73]|abstract[75]	new[71]|giv[73]|giv[75]	coref	13-8[102_75]
9-31	1634-1638	side	abstract[71]|abstract[73]|abstract|abstract[75]	new[71]|giv[73]|new|giv[75]	_	_
9-32	1639-1646	effects	abstract[71]|abstract[73]|abstract[75]	new[71]|giv[73]|giv[75]	_	_
9-33	1647-1648	,	abstract[71]|abstract[73]|abstract[75]	new[71]|giv[73]|giv[75]	_	_
9-34	1649-1660	suitability	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-35	1661-1664	for	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-36	1665-1672	chronic	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-37	1673-1683	treatments	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-38	1684-1685	,	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-39	1686-1699	marketability	abstract[71]|abstract[73]|abstract[75]|abstract[76]|abstract	new[71]|giv[73]|giv[75]|new[76]|new	_	_
9-40	1700-1701	,	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-41	1702-1705	and	abstract[71]|abstract[73]|abstract[75]|abstract[76]	new[71]|giv[73]|giv[75]|new[76]	_	_
9-42	1706-1712	safety	abstract[71]|abstract[73]|abstract[75]|abstract[76]|abstract	new[71]|giv[73]|giv[75]|new[76]|new	coref	12-8[100_0]
9-43	1713-1714	.	_	_	_	_

#Text=Here we focus our attention on pterostilbene ( Pt ; 3,5-dimethylresveratrol ) , an analogue of resveratrol that differs from the latter for the presence of two methyl groups .
10-1	1715-1719	Here	_	_	_	_
10-2	1720-1722	we	person	acc	ana	10-4
10-3	1723-1728	focus	_	_	_	_
10-4	1729-1732	our	person|abstract[81]	giv|new[81]	ana	24-16
10-5	1733-1742	attention	abstract[81]	new[81]	_	_
10-6	1743-1745	on	_	_	_	_
10-7	1746-1759	pterostilbene	abstract	new	appos	10-9
10-8	1760-1761	(	_	_	_	_
10-9	1762-1764	Pt	abstract	giv	coref	13-1
10-10	1765-1766	;	_	_	_	_
10-11	1767-1790	3,5-dimethylresveratrol	abstract	new	_	_
10-12	1791-1792	)	_	_	_	_
10-13	1793-1794	,	_	_	_	_
10-14	1795-1797	an	substance[85]	new[85]	ana	11-1[0_85]
10-15	1798-1806	analogue	substance[85]	new[85]	_	_
10-16	1807-1809	of	substance[85]	new[85]	_	_
10-17	1810-1821	resveratrol	substance[85]|object	new[85]|new	coref	11-16[98_0]
10-18	1822-1826	that	_	_	_	_
10-19	1827-1834	differs	_	_	_	_
10-20	1835-1839	from	_	_	_	_
10-21	1840-1843	the	_	_	_	_
10-22	1844-1850	latter	_	_	_	_
10-23	1851-1854	for	_	_	_	_
10-24	1855-1858	the	abstract[87]	new[87]	_	_
10-25	1859-1867	presence	abstract[87]	new[87]	_	_
10-26	1868-1870	of	abstract[87]	new[87]	_	_
10-27	1871-1874	two	abstract[87]|person[89]	new[87]|new[89]	coref	24-16[210_89]
10-28	1875-1881	methyl	abstract[87]|organization|person[89]	new[87]|new|new[89]	_	_
10-29	1882-1888	groups	abstract[87]|person[89]	new[87]|new[89]	_	_
10-30	1889-1890	.	_	_	_	_

#Text=Its increased lipophilicity accounts for its ability to reach higher tissue levels in comparison to resveratrol ’s .
11-1	1891-1894	Its	substance|abstract[92]	giv|new[92]	ana	11-6
11-2	1895-1904	increased	abstract[92]	new[92]	_	_
11-3	1905-1918	lipophilicity	substance|abstract[92]	new|new[92]	_	_
11-4	1919-1927	accounts	abstract[92]	new[92]	_	_
11-5	1928-1931	for	abstract[92]	new[92]	_	_
11-6	1932-1935	its	abstract[92]|substance|abstract[94]	new[92]|giv|new[94]	coref	22-9[195_94]
11-7	1936-1943	ability	abstract[92]|abstract[94]	new[92]|new[94]	_	_
11-8	1944-1946	to	_	_	_	_
11-9	1947-1952	reach	_	_	_	_
11-10	1953-1959	higher	abstract[96]	new[96]	coref	26-25[233_96]
11-11	1960-1966	tissue	object|abstract[96]	new|new[96]	coref	14-41[126_0]
11-12	1967-1973	levels	abstract[96]	new[96]	_	_
11-13	1974-1976	in	_	_	_	_
11-14	1977-1987	comparison	abstract[97]	new[97]	_	_
11-15	1988-1990	to	abstract[97]	new[97]	_	_
11-16	1991-2002	resveratrol	abstract[97]|object[98]	new[97]|giv[98]	_	_
11-17	2003-2005	’s	abstract[97]|object[98]	new[97]|giv[98]	_	_
11-18	2006-2007	.	_	_	_	_

#Text=Moreover , there is no concern about its safety .
12-1	2008-2016	Moreover	_	_	_	_
12-2	2017-2018	,	_	_	_	_
12-3	2019-2024	there	_	_	_	_
12-4	2025-2027	is	_	_	_	_
12-5	2028-2030	no	abstract[99]	new[99]	_	_
12-6	2031-2038	concern	abstract[99]	new[99]	_	_
12-7	2039-2044	about	abstract[99]	new[99]	_	_
12-8	2045-2048	its	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
12-9	2049-2055	safety	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
12-10	2056-2057	.	_	_	_	_

#Text=Pterostilbene has already been shown to have positive effects in combating obesity and related disorders .
13-1	2058-2071	Pterostilbene	substance	giv	coref	14-7
13-2	2072-2075	has	_	_	_	_
13-3	2076-2083	already	_	_	_	_
13-4	2084-2088	been	_	_	_	_
13-5	2089-2094	shown	_	_	_	_
13-6	2095-2097	to	_	_	_	_
13-7	2098-2102	have	_	_	_	_
13-8	2103-2111	positive	abstract[102]	giv[102]	coref	15-5[133_102]
13-9	2112-2119	effects	abstract[102]	giv[102]	_	_
13-10	2120-2122	in	_	_	_	_
13-11	2123-2132	combating	_	_	_	_
13-12	2133-2140	obesity	abstract|abstract[104]	giv|giv[104]	coref|coref	14-5|16-7[139_104]
13-13	2141-2144	and	abstract[104]	giv[104]	_	_
13-14	2145-2152	related	abstract[104]|abstract[105]	giv[104]|giv[105]	_	_
13-15	2153-2162	disorders	abstract[104]|abstract[105]	giv[104]|giv[105]	_	_
13-16	2163-2164	.	_	_	_	_

#Text=In rat models of obesity , Pt reduces fat accumulation and ameliorates liver steatosis modulating lipolysis , lipogenesis , fatty acid oxidation , improves glycemic control by modulating glycolysis , gluconeogenesis , and glucose uptake , increases thermogenic markers in brown adipose tissue , and induces changes in the gut microbiota towards a healthier composition .
14-1	2165-2167	In	_	_	_	_
14-2	2168-2171	rat	animal|abstract[107]	new|new[107]	_	_
14-3	2172-2178	models	abstract[107]	new[107]	_	_
14-4	2179-2181	of	abstract[107]	new[107]	_	_
14-5	2182-2189	obesity	abstract[107]|abstract	new[107]|giv	coref	16-7
14-6	2190-2191	,	_	_	_	_
14-7	2192-2194	Pt	substance	giv	coref	15-3
14-8	2195-2202	reduces	_	_	_	_
14-9	2203-2206	fat	substance|abstract[111]	giv|new[111]	coref	21-8
14-10	2207-2219	accumulation	abstract[111]	new[111]	_	_
14-11	2220-2223	and	_	_	_	_
14-12	2224-2235	ameliorates	_	_	_	_
14-13	2236-2241	liver	object|abstract[113]|object[114]	new|new[113]|new[114]	_	_
14-14	2242-2251	steatosis	abstract[113]|object[114]	new[113]|new[114]	_	_
14-15	2252-2262	modulating	object[114]	new[114]	_	_
14-16	2263-2272	lipolysis	object[114]	new[114]	_	_
14-17	2273-2274	,	_	_	_	_
14-18	2275-2286	lipogenesis	substance	new	_	_
14-19	2287-2288	,	_	_	_	_
14-20	2289-2294	fatty	abstract[117]	new[117]	_	_
14-21	2295-2299	acid	substance|abstract[117]	new|new[117]	ana	15-5
14-22	2300-2309	oxidation	abstract[117]	new[117]	_	_
14-23	2310-2311	,	_	_	_	_
14-24	2312-2320	improves	_	_	_	_
14-25	2321-2329	glycemic	abstract|abstract[119]	new|new[119]	_	_
14-26	2330-2337	control	abstract[119]	new[119]	_	_
14-27	2338-2340	by	_	_	_	_
14-28	2341-2351	modulating	_	_	_	_
14-29	2352-2362	glycolysis	substance	new	_	_
14-30	2363-2364	,	_	_	_	_
14-31	2365-2380	gluconeogenesis	substance	new	_	_
14-32	2381-2382	,	_	_	_	_
14-33	2383-2386	and	_	_	_	_
14-34	2387-2394	glucose	substance|abstract[123]	new|new[123]	coref	25-18
14-35	2395-2401	uptake	abstract[123]	new[123]	_	_
14-36	2402-2403	,	_	_	_	_
14-37	2404-2413	increases	_	_	_	_
14-38	2414-2425	thermogenic	abstract[124]	new[124]	_	_
14-39	2426-2433	markers	abstract[124]	new[124]	_	_
14-40	2434-2436	in	abstract[124]	new[124]	_	_
14-41	2437-2442	brown	abstract[124]|object[126]	new[124]|giv[126]	coref	15-10[0_126]
14-42	2443-2450	adipose	abstract[124]|abstract|object[126]	new[124]|new|giv[126]	coref	15-9
14-43	2451-2457	tissue	abstract[124]|object[126]	new[124]|giv[126]	_	_
14-44	2458-2459	,	_	_	_	_
14-45	2460-2463	and	_	_	_	_
14-46	2464-2471	induces	_	_	_	_
14-47	2472-2479	changes	abstract	giv	_	_
14-48	2480-2482	in	_	_	_	_
14-49	2483-2486	the	place[129]	new[129]	_	_
14-50	2487-2490	gut	abstract|place[129]	new|new[129]	_	_
14-51	2491-2501	microbiota	place[129]	new[129]	_	_
14-52	2502-2509	towards	place[129]	new[129]	_	_
14-53	2510-2511	a	place[129]|abstract[130]	new[129]|new[130]	_	_
14-54	2512-2521	healthier	place[129]|abstract[130]	new[129]|new[130]	_	_
14-55	2522-2533	composition	place[129]|abstract[130]	new[129]|new[130]	_	_
14-56	2534-2535	.	_	_	_	_

#Text=Furthermore , Pt exerts its beneficial effects combating adipose tissue inflammation .
15-1	2536-2547	Furthermore	_	_	_	_
15-2	2548-2549	,	_	_	_	_
15-3	2550-2552	Pt	object	giv	coref	22-12
15-4	2553-2559	exerts	_	_	_	_
15-5	2560-2563	its	substance|abstract[133]	giv|giv[133]	coref	23-1[200_133]
15-6	2564-2574	beneficial	abstract[133]	giv[133]	_	_
15-7	2575-2582	effects	abstract[133]	giv[133]	_	_
15-8	2583-2592	combating	_	_	_	_
15-9	2593-2600	adipose	abstract|abstract[136]	giv|new[136]	coref	17-14
15-10	2601-2607	tissue	object|abstract[136]	giv|new[136]	_	_
15-11	2608-2620	inflammation	abstract[136]	new[136]	_	_
15-12	2621-2622	.	_	_	_	_

#Text=An interesting therapeutic target for treating obesity and metabolic syndrome is represented by beige ( or brite , i. e. , brown-in-white ) adipocytes .
16-1	2623-2625	An	abstract[137]	new[137]	_	_
16-2	2626-2637	interesting	abstract[137]	new[137]	_	_
16-3	2638-2649	therapeutic	abstract[137]	new[137]	_	_
16-4	2650-2656	target	abstract[137]	new[137]	_	_
16-5	2657-2660	for	_	_	_	_
16-6	2661-2669	treating	_	_	_	_
16-7	2670-2677	obesity	abstract|abstract[139]	giv|giv[139]	coref	20-51
16-8	2678-2681	and	abstract[139]	giv[139]	_	_
16-9	2682-2691	metabolic	abstract[139]|person|abstract[141]	giv[139]|new|new[141]	_	_
16-10	2692-2700	syndrome	abstract[139]|abstract[141]	giv[139]|new[141]	_	_
16-11	2701-2703	is	_	_	_	_
16-12	2704-2715	represented	_	_	_	_
16-13	2716-2718	by	_	_	_	_
16-14	2719-2724	beige	substance	new	_	_
16-15	2725-2726	(	_	_	_	_
16-16	2727-2729	or	_	_	_	_
16-17	2730-2735	brite	abstract	new	_	_
16-18	2736-2737	,	_	_	_	_
16-19	2738-2740	i.	_	_	_	_
16-20	2741-2743	e.	_	_	_	_
16-21	2744-2745	,	_	_	_	_
16-22	2746-2760	brown-in-white	abstract	new	_	_
16-23	2761-2762	)	_	_	_	_
16-24	2763-2773	adipocytes	object	new	coref	17-8[148_0]
16-25	2774-2775	.	_	_	_	_

#Text=These cells are an inducible form of thermogenic adipocytes residing in subcutaneous white adipose tissue ( WAT ) and are also found in human adults .
17-1	2776-2781	These	object[146]	new[146]	coref	17-4[147_146]
17-2	2782-2787	cells	object[146]	new[146]	_	_
17-3	2788-2791	are	_	_	_	_
17-4	2792-2794	an	object[147]	giv[147]	coref	18-15[158_147]
17-5	2795-2804	inducible	object[147]	giv[147]	_	_
17-6	2805-2809	form	object[147]	giv[147]	_	_
17-7	2810-2812	of	object[147]	giv[147]	_	_
17-8	2813-2824	thermogenic	object[147]|object[148]	giv[147]|giv[148]	coref	18-1[153_148]
17-9	2825-2835	adipocytes	object[147]|object[148]	giv[147]|giv[148]	_	_
17-10	2836-2844	residing	_	_	_	_
17-11	2845-2847	in	_	_	_	_
17-12	2848-2860	subcutaneous	object[150]	new[150]	appos	17-17[0_150]
17-13	2861-2866	white	object[150]	new[150]	_	_
17-14	2867-2874	adipose	abstract|object[150]	giv|new[150]	_	_
17-15	2875-2881	tissue	object[150]	new[150]	_	_
17-16	2882-2883	(	_	_	_	_
17-17	2884-2887	WAT	object	giv	coref	20-9
17-18	2888-2889	)	_	_	_	_
17-19	2890-2893	and	_	_	_	_
17-20	2894-2897	are	_	_	_	_
17-21	2898-2902	also	_	_	_	_
17-22	2903-2908	found	_	_	_	_
17-23	2909-2911	in	_	_	_	_
17-24	2912-2917	human	person[152]	new[152]	ana	19-1[0_152]
17-25	2918-2924	adults	person[152]	new[152]	_	_
17-26	2925-2926	.	_	_	_	_

#Text=Beige adipocytes can derive from white adipocyte trans differentiation and from the differentiation of adipogenic progenitor cells .
18-1	2927-2932	Beige	object[153]	giv[153]	coref	19-20[164_153]
18-2	2933-2943	adipocytes	object[153]	giv[153]	_	_
18-3	2944-2947	can	_	_	_	_
18-4	2948-2954	derive	_	_	_	_
18-5	2955-2959	from	_	_	_	_
18-6	2960-2965	white	abstract[156]	new[156]	coref	18-12[157_156]
18-7	2966-2975	adipocyte	object|abstract[156]	new|new[156]	_	_
18-8	2976-2981	trans	person|abstract[156]	new|new[156]	_	_
18-9	2982-2997	differentiation	abstract[156]	new[156]	_	_
18-10	2998-3001	and	_	_	_	_
18-11	3002-3006	from	_	_	_	_
18-12	3007-3010	the	abstract[157]	giv[157]	_	_
18-13	3011-3026	differentiation	abstract[157]	giv[157]	_	_
18-14	3027-3029	of	abstract[157]	giv[157]	_	_
18-15	3030-3040	adipogenic	abstract[157]|object[158]	giv[157]|giv[158]	_	_
18-16	3041-3051	progenitor	abstract[157]|object[158]	giv[157]|giv[158]	_	_
18-17	3052-3057	cells	abstract[157]|object[158]	giv[157]|giv[158]	_	_
18-18	3058-3059	.	_	_	_	_

#Text=They express a set of beige-specific genes , such as Cited1 and Tbx1 , but also have similarities with brown adipocytes , including abundant mitochondria , multilocular lipid droplets and expression of brown-specific genes such as uncoupling protein 1 ( UCP1 ) and Cidea ; similar to brown adipocytes , they are able to dissipate energy as heat .
19-1	3060-3064	They	person	giv	ana	19-51
19-2	3065-3072	express	_	_	_	_
19-3	3073-3074	a	abstract[160]	new[160]	coref	19-33[169_160]
19-4	3075-3078	set	abstract[160]	new[160]	_	_
19-5	3079-3081	of	abstract[160]	new[160]	_	_
19-6	3082-3096	beige-specific	abstract[160]	new[160]	_	_
19-7	3097-3102	genes	abstract[160]	new[160]	_	_
19-8	3103-3104	,	abstract[160]	new[160]	_	_
19-9	3105-3109	such	abstract[160]	new[160]	_	_
19-10	3110-3112	as	abstract[160]	new[160]	_	_
19-11	3113-3119	Cited1	abstract[160]|abstract	new[160]|new	_	_
19-12	3120-3123	and	abstract[160]	new[160]	_	_
19-13	3124-3128	Tbx1	abstract[160]|abstract	new[160]|new	_	_
19-14	3129-3130	,	_	_	_	_
19-15	3131-3134	but	_	_	_	_
19-16	3135-3139	also	_	_	_	_
19-17	3140-3144	have	_	_	_	_
19-18	3145-3157	similarities	abstract[163]	new[163]	_	_
19-19	3158-3162	with	abstract[163]	new[163]	_	_
19-20	3163-3168	brown	abstract[163]|object[164]	new[163]|giv[164]	coref	19-48[173_164]
19-21	3169-3179	adipocytes	abstract[163]|object[164]	new[163]|giv[164]	_	_
19-22	3180-3181	,	abstract[163]|object[164]	new[163]|giv[164]	_	_
19-23	3182-3191	including	abstract[163]|object[164]	new[163]|giv[164]	_	_
19-24	3192-3200	abundant	abstract[163]|object[164]|object[165]	new[163]|giv[164]|new[165]	_	_
19-25	3201-3213	mitochondria	abstract[163]|object[164]|object[165]	new[163]|giv[164]|new[165]	_	_
19-26	3214-3215	,	abstract[163]|object[164]	new[163]|giv[164]	_	_
19-27	3216-3228	multilocular	abstract[163]|object[164]|object[167]	new[163]|giv[164]|new[167]	_	_
19-28	3229-3234	lipid	abstract[163]|object[164]|person|object[167]	new[163]|giv[164]|new|new[167]	_	_
19-29	3235-3243	droplets	abstract[163]|object[164]|object[167]	new[163]|giv[164]|new[167]	_	_
19-30	3244-3247	and	abstract[163]|object[164]	new[163]|giv[164]	_	_
19-31	3248-3258	expression	abstract[163]|object[164]|abstract[168]	new[163]|giv[164]|new[168]	_	_
19-32	3259-3261	of	abstract[163]|object[164]|abstract[168]	new[163]|giv[164]|new[168]	_	_
19-33	3262-3276	brown-specific	abstract[163]|object[164]|abstract[168]|abstract[169]	new[163]|giv[164]|new[168]|giv[169]	coref	26-21[230_169]
19-34	3277-3282	genes	abstract[163]|object[164]|abstract[168]|abstract[169]	new[163]|giv[164]|new[168]|giv[169]	_	_
19-35	3283-3287	such	abstract[163]|object[164]|abstract[168]|abstract[169]	new[163]|giv[164]|new[168]|giv[169]	_	_
19-36	3288-3290	as	abstract[163]|object[164]|abstract[168]|abstract[169]	new[163]|giv[164]|new[168]|giv[169]	_	_
19-37	3291-3301	uncoupling	abstract[163]|object[164]|abstract[168]|abstract[169]|substance[170]	new[163]|giv[164]|new[168]|giv[169]|new[170]	coref	26-26[0_170]
19-38	3302-3309	protein	abstract[163]|object[164]|abstract[168]|abstract[169]|substance[170]	new[163]|giv[164]|new[168]|giv[169]|new[170]	_	_
19-39	3310-3311	1	abstract[163]|object[164]|abstract[168]|abstract[169]|substance[170]	new[163]|giv[164]|new[168]|giv[169]|new[170]	_	_
19-40	3312-3313	(	_	_	_	_
19-41	3314-3318	UCP1	organization	new	coref	26-25
19-42	3319-3320	)	_	_	_	_
19-43	3321-3324	and	_	_	_	_
19-44	3325-3330	Cidea	substance[172]	new[172]	_	_
19-45	3331-3332	;	substance[172]	new[172]	_	_
19-46	3333-3340	similar	substance[172]	new[172]	_	_
19-47	3341-3343	to	_	_	_	_
19-48	3344-3349	brown	object[173]	giv[173]	coref	20-3[177_173]
19-49	3350-3360	adipocytes	object[173]	giv[173]	_	_
19-50	3361-3362	,	_	_	_	_
19-51	3363-3367	they	person	giv	_	_
19-52	3368-3371	are	_	_	_	_
19-53	3372-3376	able	_	_	_	_
19-54	3377-3379	to	_	_	_	_
19-55	3380-3389	dissipate	_	_	_	_
19-56	3390-3396	energy	abstract	new	_	_
19-57	3397-3399	as	_	_	_	_
19-58	3400-3404	heat	_	_	_	_
19-59	3405-3406	.	_	_	_	_

#Text=Induction of beige adipocytes ( i. e. , WAT browning ) can be induced by environmental or physiological stimuli ( such as cold exposure , physical activity , or thyroid hormones ) , but also pharmacologically ( for example , with PPAR agonists ) , and could prevent or combat obesity by increasing energy consumption through non-shivering thermogenesis .
20-1	3407-3416	Induction	abstract[176]	new[176]	_	_
20-2	3417-3419	of	abstract[176]	new[176]	_	_
20-3	3420-3425	beige	abstract[176]|object[177]	new[176]|giv[177]	coref	23-7[201_177]
20-4	3426-3436	adipocytes	abstract[176]|object[177]	new[176]|giv[177]	_	_
20-5	3437-3438	(	_	_	_	_
20-6	3439-3441	i.	_	_	_	_
20-7	3442-3444	e.	_	_	_	_
20-8	3445-3446	,	_	_	_	_
20-9	3447-3450	WAT	abstract|abstract[179]	giv|new[179]	coref|coref	21-8[192_179]|22-17
20-10	3451-3459	browning	abstract[179]	new[179]	_	_
20-11	3460-3461	)	_	_	_	_
20-12	3462-3465	can	_	_	_	_
20-13	3466-3468	be	_	_	_	_
20-14	3469-3476	induced	_	_	_	_
20-15	3477-3479	by	_	_	_	_
20-16	3480-3493	environmental	abstract[180]	new[180]	_	_
20-17	3494-3496	or	abstract[180]	new[180]	_	_
20-18	3497-3510	physiological	abstract[180]	new[180]	_	_
20-19	3511-3518	stimuli	abstract[180]	new[180]	_	_
20-20	3519-3520	(	abstract[180]	new[180]	_	_
20-21	3521-3525	such	abstract[180]	new[180]	_	_
20-22	3526-3528	as	abstract[180]	new[180]	_	_
20-23	3529-3533	cold	abstract[180]|abstract[181]	new[180]|new[181]	_	_
20-24	3534-3542	exposure	abstract[180]|abstract[181]	new[180]|new[181]	_	_
20-25	3543-3544	,	abstract[180]	new[180]	_	_
20-26	3545-3553	physical	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
20-27	3554-3562	activity	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
20-28	3563-3564	,	abstract[180]	new[180]	_	_
20-29	3565-3567	or	abstract[180]	new[180]	_	_
20-30	3568-3575	thyroid	abstract[180]|object|substance[184]	new[180]|new|new[184]	_	_
20-31	3576-3584	hormones	abstract[180]|substance[184]	new[180]|new[184]	_	_
20-32	3585-3586	)	abstract[180]	new[180]	_	_
20-33	3587-3588	,	_	_	_	_
20-34	3589-3592	but	_	_	_	_
20-35	3593-3597	also	_	_	_	_
20-36	3598-3615	pharmacologically	_	_	_	_
20-37	3616-3617	(	_	_	_	_
20-38	3618-3621	for	_	_	_	_
20-39	3622-3629	example	_	_	_	_
20-40	3630-3631	,	_	_	_	_
20-41	3632-3636	with	_	_	_	_
20-42	3637-3641	PPAR	organization|substance[186]	new|new[186]	_	_
20-43	3642-3650	agonists	substance[186]	new[186]	_	_
20-44	3651-3652	)	_	_	_	_
20-45	3653-3654	,	_	_	_	_
20-46	3655-3658	and	_	_	_	_
20-47	3659-3664	could	_	_	_	_
20-48	3665-3672	prevent	_	_	_	_
20-49	3673-3675	or	_	_	_	_
20-50	3676-3682	combat	_	_	_	_
20-51	3683-3690	obesity	abstract	giv	coref	23-18[204_0]
20-52	3691-3693	by	_	_	_	_
20-53	3694-3704	increasing	_	_	_	_
20-54	3705-3711	energy	abstract[188]	new[188]	_	_
20-55	3712-3723	consumption	abstract[188]	new[188]	_	_
20-56	3724-3731	through	_	_	_	_
20-57	3732-3745	non-shivering	abstract[189]	new[189]	_	_
20-58	3746-3759	thermogenesis	abstract[189]	new[189]	_	_
20-59	3760-3761	.	_	_	_	_

#Text=Various phytochemicals have been reported to promote fat browning .
21-1	3762-3769	Various	abstract[190]	new[190]	_	_
21-2	3770-3784	phytochemicals	abstract[190]	new[190]	_	_
21-3	3785-3789	have	_	_	_	_
21-4	3790-3794	been	_	_	_	_
21-5	3795-3803	reported	_	_	_	_
21-6	3804-3806	to	_	_	_	_
21-7	3807-3814	promote	_	_	_	_
21-8	3815-3818	fat	substance|abstract[192]	giv|giv[192]	_	_
21-9	3819-3827	browning	abstract[192]	giv[192]	_	_
21-10	3828-3829	.	_	_	_	_

#Text=The aim of this study was to investigate the ability of Pt to do it in WAT .
22-1	3830-3833	The	abstract[193]	new[193]	_	_
22-2	3834-3837	aim	abstract[193]	new[193]	_	_
22-3	3838-3840	of	abstract[193]	new[193]	_	_
22-4	3841-3845	this	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-5	3846-3851	study	abstract[193]|abstract[194]	new[193]|new[194]	_	_
22-6	3852-3855	was	_	_	_	_
22-7	3856-3858	to	_	_	_	_
22-8	3859-3870	investigate	_	_	_	_
22-9	3871-3874	the	abstract[195]	giv[195]	ana	22-15[0_195]
22-10	3875-3882	ability	abstract[195]	giv[195]	_	_
22-11	3883-3885	of	abstract[195]	giv[195]	_	_
22-12	3886-3888	Pt	abstract[195]|object	giv[195]|giv	coref	24-34
22-13	3889-3891	to	_	_	_	_
22-14	3892-3894	do	_	_	_	_
22-15	3895-3897	it	abstract	giv	_	_
22-16	3898-3900	in	_	_	_	_
22-17	3901-3904	WAT	abstract	giv	ana	23-1
22-18	3905-3906	.	_	_	_	_

#Text=Its effects were first assayed on cultured 3T3-L1 adipocytes , and then in a mouse model of diet-induced obesity .
23-1	3907-3910	Its	abstract|abstract[200]	giv|giv[200]	coref	26-8
23-2	3911-3918	effects	abstract[200]	giv[200]	_	_
23-3	3919-3923	were	_	_	_	_
23-4	3924-3929	first	_	_	_	_
23-5	3930-3937	assayed	_	_	_	_
23-6	3938-3940	on	_	_	_	_
23-7	3941-3949	cultured	object[201]	giv[201]	_	_
23-8	3950-3956	3T3-L1	object[201]	giv[201]	_	_
23-9	3957-3967	adipocytes	object[201]	giv[201]	_	_
23-10	3968-3969	,	_	_	_	_
23-11	3970-3973	and	_	_	_	_
23-12	3974-3978	then	_	_	_	_
23-13	3979-3981	in	_	_	_	_
23-14	3982-3983	a	abstract[203]	new[203]	_	_
23-15	3984-3989	mouse	animal|abstract[203]	new|new[203]	_	_
23-16	3990-3995	model	abstract[203]	new[203]	_	_
23-17	3996-3998	of	abstract[203]	new[203]	_	_
23-18	3999-4011	diet-induced	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
23-19	4012-4019	obesity	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
23-20	4020-4021	.	_	_	_	_

#Text=To take into account possible gender-specific differences , both females and males were included in our experimental groups ; a 30 week-long treatment was performed , to highlight long-term effects of a chronic Pt supplementation .
24-1	4022-4024	To	_	_	_	_
24-2	4025-4029	take	_	_	_	_
24-3	4030-4034	into	_	_	_	_
24-4	4035-4042	account	abstract	new	_	_
24-5	4043-4051	possible	abstract[206]	new[206]	_	_
24-6	4052-4067	gender-specific	abstract[206]	new[206]	_	_
24-7	4068-4079	differences	abstract[206]	new[206]	_	_
24-8	4080-4081	,	_	_	_	_
24-9	4082-4086	both	person[207]	new[207]	_	_
24-10	4087-4094	females	person[207]	new[207]	_	_
24-11	4095-4098	and	_	_	_	_
24-12	4099-4104	males	person	new	_	_
24-13	4105-4109	were	_	_	_	_
24-14	4110-4118	included	_	_	_	_
24-15	4119-4121	in	_	_	_	_
24-16	4122-4125	our	person|person[210]	giv|giv[210]	ana	25-1
24-17	4126-4138	experimental	person[210]	giv[210]	_	_
24-18	4139-4145	groups	person[210]	giv[210]	_	_
24-19	4146-4147	;	_	_	_	_
24-20	4148-4149	a	event[211]	giv[211]	_	_
24-21	4150-4152	30	event[211]	giv[211]	_	_
24-22	4153-4162	week-long	event[211]	giv[211]	_	_
24-23	4163-4172	treatment	event[211]	giv[211]	_	_
24-24	4173-4176	was	_	_	_	_
24-25	4177-4186	performed	_	_	_	_
24-26	4187-4188	,	_	_	_	_
24-27	4189-4191	to	_	_	_	_
24-28	4192-4201	highlight	_	_	_	_
24-29	4202-4211	long-term	abstract[212]	new[212]	_	_
24-30	4212-4219	effects	abstract[212]	new[212]	_	_
24-31	4220-4222	of	abstract[212]	new[212]	_	_
24-32	4223-4224	a	abstract[212]|abstract[214]	new[212]|new[214]	_	_
24-33	4225-4232	chronic	abstract[212]|abstract[214]	new[212]|new[214]	_	_
24-34	4233-4235	Pt	abstract[212]|substance|abstract[214]	new[212]|giv|new[214]	coref	25-4
24-35	4236-4251	supplementation	abstract[212]|abstract[214]	new[212]|new[214]	_	_
24-36	4252-4253	.	_	_	_	_

#Text=We found that Pt diminished body weight gain induced by a high-fat diet regimen ; also , glucose homeostasis was partially preserved , at least up to week 18 .
25-1	4254-4256	We	person	giv	_	_
25-2	4257-4262	found	_	_	_	_
25-3	4263-4267	that	_	_	_	_
25-4	4268-4270	Pt	substance|abstract[219]	giv|new[219]	coref	26-3
25-5	4271-4281	diminished	abstract[219]	new[219]	_	_
25-6	4282-4286	body	object|abstract[219]	new|new[219]	_	_
25-7	4287-4293	weight	abstract|abstract[219]	new|new[219]	_	_
25-8	4294-4298	gain	abstract[219]	new[219]	_	_
25-9	4299-4306	induced	_	_	_	_
25-10	4307-4309	by	_	_	_	_
25-11	4310-4311	a	event[221]	new[221]	_	_
25-12	4312-4320	high-fat	event[221]	new[221]	_	_
25-13	4321-4325	diet	event|event[221]	new|new[221]	_	_
25-14	4326-4333	regimen	event[221]	new[221]	_	_
25-15	4334-4335	;	_	_	_	_
25-16	4336-4340	also	_	_	_	_
25-17	4341-4342	,	_	_	_	_
25-18	4343-4350	glucose	substance|abstract[223]	giv|new[223]	_	_
25-19	4351-4362	homeostasis	abstract[223]	new[223]	_	_
25-20	4363-4366	was	_	_	_	_
25-21	4367-4376	partially	_	_	_	_
25-22	4377-4386	preserved	_	_	_	_
25-23	4387-4388	,	_	_	_	_
25-24	4389-4391	at	_	_	_	_
25-25	4392-4397	least	_	_	_	_
25-26	4398-4400	up	_	_	_	_
25-27	4401-4403	to	_	_	_	_
25-28	4404-4408	week	time[224]	new[224]	_	_
25-29	4409-4411	18	time[224]	new[224]	_	_
25-30	4412-4413	.	_	_	_	_

#Text=Interestingly , Pt was able to induce WAT browning , leading to an increase in the transcription of beige- and brown-related genes and of UCP1 protein levels , which , however , did not achieve significance .
26-1	4414-4427	Interestingly	_	_	_	_
26-2	4428-4429	,	_	_	_	_
26-3	4430-4432	Pt	abstract	giv	_	_
26-4	4433-4436	was	_	_	_	_
26-5	4437-4441	able	_	_	_	_
26-6	4442-4444	to	_	_	_	_
26-7	4445-4451	induce	_	_	_	_
26-8	4452-4455	WAT	abstract	giv	_	_
26-9	4456-4464	browning	_	_	_	_
26-10	4465-4466	,	_	_	_	_
26-11	4467-4474	leading	_	_	_	_
26-12	4475-4477	to	_	_	_	_
26-13	4478-4480	an	abstract[227]	new[227]	_	_
26-14	4481-4489	increase	abstract[227]	new[227]	_	_
26-15	4490-4492	in	abstract[227]	new[227]	_	_
26-16	4493-4496	the	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-17	4497-4510	transcription	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-18	4511-4513	of	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-19	4514-4520	beige-	abstract[227]|abstract[228]|abstract	new[227]|new[228]|new	_	_
26-20	4521-4524	and	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-21	4525-4538	brown-related	abstract[227]|abstract[228]|abstract[230]	new[227]|new[228]|giv[230]	_	_
26-22	4539-4544	genes	abstract[227]|abstract[228]|abstract[230]	new[227]|new[228]|giv[230]	_	_
26-23	4545-4548	and	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-24	4549-4551	of	abstract[227]|abstract[228]	new[227]|new[228]	_	_
26-25	4552-4556	UCP1	abstract[227]|abstract[228]|abstract|abstract[233]	new[227]|new[228]|giv|giv[233]	_	_
26-26	4557-4564	protein	abstract[227]|abstract[228]|substance|abstract[233]	new[227]|new[228]|giv|giv[233]	_	_
26-27	4565-4571	levels	abstract[227]|abstract[228]|abstract[233]	new[227]|new[228]|giv[233]	_	_
26-28	4572-4573	,	_	_	_	_
26-29	4574-4579	which	_	_	_	_
26-30	4580-4581	,	_	_	_	_
26-31	4582-4589	however	_	_	_	_
26-32	4590-4591	,	_	_	_	_
26-33	4592-4595	did	_	_	_	_
26-34	4596-4599	not	_	_	_	_
26-35	4600-4607	achieve	_	_	_	_
26-36	4608-4620	significance	abstract	new	_	_
26-37	4621-4622	.	_	_	_	_
